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Abstract
Introduction: Phenotyping allergic rhinitis (AR) by immuno-
globulin E (IgE) sensitivity and comorbidities may help char-
acterize AR and provide a framework for treatment deci-
sions. Methods: This prospective, noninterventional study 
evaluated the effectiveness of MP-AzeFlu (azelastine hydro-
chloride plus fluticasone propionate intranasal spray formu-
lation) across AR phenotypes. Patients with moderate-to- 
severe seasonal or perennial AR for whom MP-AzeFlu was 
prescribed were enrolled. AR subpopulations (ARPs) were 
assigned based on the classification of IgE response and co-
morbidities. AR symptoms over the previous 24 h were doc-
umented using an AR visual analog scale (AR-VAS), with rat-
ings from “not at all bothersome” (0 mm) to “extremely both-
ersome” (100 mm), at the inclusion visit and on days 1, 3, 7, 
and the last day of the study (approximately day 14). AR qual-
ity-of-life measures were recorded using a VAS. Results: A 
total of 1,103 patients with AR were included. Mean baseline 
AR-VAS scores ranged from 70.3 to 75.1 mm (severe) across 
ARPs. In the overall population, 86.6% of patients responded 
to treatment (AR-VAS score <50 mm on ≥1 days). In the ARPs, 
response rates ranged from 79.3 to 89.6%. Mean reduction 
in AR-VAS scores ranged from 47.9 to 40.9 mm, a decrease 
from severe to mild across all ARPs. Quality-of-life VAS scores 
were similarly reduced in the total population and ARPs. Dis-
cussion/Conclusion: MP-AzeFlu treatment reduced VAS se-
verity and quality-of-life scores from baseline in the total 
population and ARPs, supporting MP-AzeFlu as an effective 
treatment for all patients with moderate-to-severe AR, re-
gardless of AR phenotype or comorbidities.
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Introduction
Allergic rhinitis (AR) is a common atopic disorder that 
frequently co-occurs with other conditions [1]. Common 
atopic comorbidities include asthma, conjunctivitis, atopic 
dermatitis, food allergy, urticaria, and anaphylaxis [1–3]. 
Furthermore, other disorders are related to AR, presenting 
as multimorbid rhinosinusitis, middle ear problems (e.g., 
otitis media), and throat and laryngeal problems [1].
The presence of allergic comorbidities is often linked 
with the persistence or severity of allergic diseases, in-
cluding AR. When the presence of comorbidities is con-
sidered in conjunction with specific immunoglobulin E 
(IgE) sensitization characteristics, phenotypic patterns 
emerge [4, 5]. Therefore, the presence of comorbidities 
and IgE polysensitization have been utilized to develop a 
new phenotypic classification system for allergic diseases. 
According to the MeDALL study by Bousquet and col-
leagues, the 3 primary phenotypes are IgE response to a 
single environmental allergen with no family history (low 
IgE responders), polyclonal IgE response to environmen-
tal allergens with family history (high IgE responders), 
and nonallergic polyclonal IgE response without family 
history (late-onset and local polyclonal IgE disease) [6]. 
Patients who do not fit within 1 of these 3 classifications 
are considered to have an intermediate phenotype. Phe-
notyping AR using specific IgE sensitization and family 
history of disease may help characterize allergic diseases, 
provide a clinical framework to inform treatment deci-
sions, and improve the design of clinical trials [6].
Treatments for AR include oral H1 antihistamines, in-
tranasal corticosteroid (INCS) sprays, or intranasal H1 
antihistamine (INAH) sprays [7]. For some patients with 
moderate-to-severe persistent AR, INCS-INAH combi-
nation therapies may be required. In the Allergic Rhinitis 
and its Impact on Asthma (ARIA) 2016 guideline update, 
treatment with an INCS-INAH combination formulation 
is a first-line recommendation for patients with AR [8].
Azelastine hydrochloride has been formulated with 
fluticasone propionate in a single spray (MP-AzeFlu) for 
the treatment of AR. MP-AzeFlu is a safe, effective, and 
rapid-acting option for treating AR symptoms, including 
nasal congestion [9], loss of smell [10], and nasal hyper-
reactivity [11]. MP-AzeFlu has demonstrated a superior 
effect compared with other intranasal drugs in mono-
therapy at both the symptom and anti-inflammatory lev-
els [12, 13]. In this analysis of a real-life study, the ob-
jective was to evaluate the effectiveness of MP-AzeFlu 
(azelastine hydrochloride/fluticasone propionate nasal 
spray) across AR phenotypes.
Materials and Methods
Study Design
This multinational, multicenter, prospective, nonintervention-
al, real-life study was conducted in Austria, Germany, Czech Re-
public, Hungary, The Netherlands, and Ireland. Ethics approval 
was obtained according to the national laws and guidelines for 
each country. The study was conducted from February 21, 2018, 
to April 30, 2019. General practitioners, allergists, otorhinolaryn-
gologists, pneumonologists, dermatologists, and pediatricians 
participated in the study.
The study period was approximately 2 weeks long and con-
sisted of an inclusion visit (day 0) and a control visit on or around 
day 14 (last day), allowing for some flexibility depending on usual 
clinical practice. Patients received 5 patient cards at the inclusion 
visit to record symptom scores and other outcomes using an AR 
visual analog scale (AR-VAS, 0–100 mm). Physicians collected pa-
tient cards at the control visit or by mail.
All patients enrolled in the study received MP-AzeFlu (Dymis-
ta®, Mylan Pharmaceuticals), which was prescribed by physicians 
independently and before the decision to include a patient in the 
study, for 14 consecutive days. Prior to administration, physicians 
confirmed that patients understood the instructions for use. MP-
AzeFlu was dosed as 1 spray in each nostril twice daily (total daily 
dose, 548 μg azelastine hydrochloride, and 200 μg fluticasone pro-
pionate), as recommended in the prescribing information [14].
Participants
Patients had moderate-to-severe (defined by meeting at least 1 
of the following 4 criteria: impaired sleep, impaired daily activities, 
impaired work productivity/school performance, or troublesome 
symptoms) seasonal AR or perennial AR according to ARIA crite-
ria [15]. For all participants, MP-AzeFlu was prescribed for the 
first time at study initiation.
Inclusion criteria were first-time prescription of MP-AzeFlu ac-
cording to the summary of product characteristics, age 12 years or 
older, moderate-to-severe seasonal AR or perennial AR, acute symp-
toms of AR (AR-VAS ≥50 mm, suggestive of uncontrolled AR) [16] 
on the day of inclusion, written informed consent by patient and (if 
applicable) by caregiver for patients younger than 18 years, and abil-
ity to understand the instructions for the use of MP-AzeFlu accord-
ing to the summary of product characteristics and patient leaflet. 
Exclusion criteria were known allergic reaction to MP-AzeFlu or any 
of its ingredients, pregnancy or planned pregnancy, breastfeeding, 
inability to provide informed consent, or missing consent.
Study Measures
On day 0, the physician documented patient data, including 
demographics, medical history of AR, number and types of aller-
gens, allergies and other comorbidities, specific IgE response re-
sults according to prior serum IgE testing or skin prick testing, and 
family history of allergies. The numbers and types of allergens were 
defined by either the results of specific IgE testing or answers to a 
question about known allergic sensitization. If both specific IgE 
test results and survey question response data were available, the 
higher number of allergens was chosen for the classification. For 
example, a patient with 4 allergens identified by specific IgE testing 
and 5 allergens selected in the survey was considered to have 5 al-
lergens for the purposes of the study. Prior specific IgE testing re-
sults were available for 372 of the 1,103 patients in the study.
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Patient data were used to assign AR subpopulations (ARPs) 
for all patients. The ARPs are described in Table 1. ARP1, ARP2, 
ARP3, and ARP4 were defined based on the classification of IgE-
mediated diseases as described by Bousquet and colleagues 
[6]. ARP1 through ARP4 were mutually exclusive groups, but pa-
tients in ARP1 through ARP4 could also be assigned to ARP5 on 
the basis of the presence of comorbidities.
AR symptoms over the past 24 h were documented using a 
printed, single-line VAS with ratings from “not at all bothersome” 
(0 mm) to “extremely bothersome” (100 mm). How bothersome a 
patient found his or her symptoms over the past 24 h was recorded 
during the inclusion visit (day 0), and on days 1, 3, 7, and the last 
study day (on or around day 14). The primary outcome was treat-
ment response, which was considered an AR-VAS score of <50 
mm (suggestive of AR control) [16] at least once during the study.
Secondary objectives included AR quality-of-life VAS mea-
sures, using some of the criteria for ARIA severity classification: 
troublesomeness of sleep quality; daily home, work, or school ac-
tivities; daily social activities; and daily outdoor activities. These 
measures were recorded on days 0 and 7, as well as on the last day 
of the study.
Statistical Methods
Subpopulation analyses were performed for patients with dif-
ferent ARPs, countries, age ranges, and sexes. Statistical analyses 
were performed using the statistical software package SAS (SAS 
Institute Inc., Cary, NC, USA) version 9.4 or higher.
Results
Study Population
Of the 1,154 patients enrolled in the study, 51 were ex-
cluded because their data had not been confirmed by the 
physician, leaving 1,103 patients for the final analysis (full 
analysis set). Within the past year, the majority of patients 
(82.9%) had used ≥1 treatments for symptomatic AR, and 
62% used ≥2 allergy medications. Patients comprising the 
full analysis set had a mean (standard deviation) age of 
40.0 (16.6) years, and 56.6% were female. Mean baseline 
VAS for overall AR symptoms ranged from 70.3 to 75.1 
mm (severe) across the different ARPs. Baseline demo-
graphics, including baseline VAS scores, are outlined in 
Table 2. Previous symptomatic AR treatments during the 
past year are reported in Table 3.
Effectiveness of MP-AzeFlu by ARP
Response to treatment was defined as a reduction in 
AR symptoms to <50 mm on the VAS, the cutoff that dif-
ferentiates controlled AR from uncontrolled AR [16], in 
≥1 measurements. The response rate in the full analysis 
set was 86.6%. In the ARPs, the response rates ranged 
from 79.3 to 89.6%. By day 1, the median (interquartile 
range) change in VAS was 10 mm (25.3 mm); by day 3, 
the median (interquartile range) change was 22 mm (40.1 
mm). By the last day, the median change was 49 mm (62.3 
mm).
From day 1 through the last day of the study, mean 
AR-VAS scores decreased across all subpopulations (p < 
0.0001; shown in Fig. 1). Mean reduction in VAS score 
from baseline to the last day ranged from 47.9 mm (ARP2) 
to 40.9 mm (ARP3). Furthermore, the rates of reduction 
of AR-VAS scores were comparable across countries, age 
ranges, and sexes.
Table 1. Allergic rhinitis subpopulations
ARPs Criteria MeDALL description [6]
ARP1 Specific IgE response restricted to 1 environmental 
allergen, without family history
Low IgE responders, both in number of components and level of 
specific IgE
ARP2 Polyclonal IgE response to >5 environmental allergens, 
with family history
High IgE responders, both in number of components and level of 
IgE; usually symptomatic, with an early-life onset and a high rate 
of comorbidities over time
ARP3 Nonallergic polyclonal IgE (patients with IgE test, but 
no increased total IgE value), without family history
Usually late-onset disease and local polyclonal IgE (e.g., local IgE 
production in the upper airway mucosa but skin prick tests and 
serum IgE testing are negative)
ARP4 Intermediate phenotypes Polyclonal IgE response without family history or IgE response 
restricted to few allergens (e.g., 2–5 allergens)
ARP5 Comorbidities, including asthma, food allergy, eczema/
atopic dermatitis, or severe allergic reaction
Not applicable
ARP, allergic rhinitis subpopulation; IgE, immunoglobulin E.
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Changes in Quality-of-Life Measures
Quality of life was evaluated using VAS scores, as 
shown in Figure 2. Changes in troublesomeness of sleep 
quality from day 0 to the last day ranged from 33.3 mm 
(ARP2) to 39.6 mm (ARP3). Changes in troublesomeness 
of daily activities at work or school from day 0 to the last 
day ranged from 35.0 mm (ARP1) to 38.6 mm (ARP2). 
Improvements in troublesomeness of daily social activi-
ties from day 0 to the last day ranged from 32.3 mm 
(ARP4) to 38.3 mm (ARP3). Finally, troublesomeness of 
daily outdoor activities from day 0 to the last day im-
proved by a range of 35.5 mm (ARP1) to 46.4 mm (ARP2).
Moderate, statistically significant correlations were 
seen between overall symptom improvement and im-
provement in sleep quality and daily activities (Pearson 
correlation coefficient = 0.40–0.46; p < 0.0001). By con-
trast, the correlations among the different activities were 
stronger (Pearson correlation coefficient = 0.44–0.82; p < 
0.0001).
Table 2. Baseline patient demographics
Baseline characteristics Full analysis set 
(N = 1,103)
ARP1 (IgE response to 1  
environmental allergy  
without family history) 
(n = 115)
ARP2 (polyclonal IgE  
response to >5 allergens  
with family history) 
(n = 89)
ARP3 (nonallergic 











Male 474 (43.0) 53 (46.1) 40 (44.9) 17 (32.1) 289 (43.4) 171 (40.6)
Female 624 (56.6) 62 (53.9) 49 (55.1) 36 (67.9) 373 (55.9) 248 (58.9)
Missing 5 (0.5) 0 0 0 5 (0.75) 2 (0.48)
Age, n (%)
12–17 years 82 (7.4) 7 (6.1) 7 (7.9) 3 (5.7) 55 (8.3) 35 (8.3)
18–65 years 937 (85.0) 94 (81.7) 78 (87.6) 48 (90.6) 573 (85.9) 353 (83.9)
>65 years 84 (7.6) 14 (12.2) 4 (4.5) 2 (3.8) 39 (5.9) 33 (7.8)
Allergic sensitization by number of allergens, n (%)
1 178 (16.1) 115 (100) 0 20 (37.7) 9 (1.35) 43 (10.2)
2–5 570 (51.7) 0 7 (7.9) 25 (47.2) 563 (84.4) 230 (54.6)
>5 176 (16.0) 0 82 (92.1) 6 (11.3) 94 (14.1) 111 (26.4)
Unknown 179 (16.2) 0 0 2 (3.8) 1 (0.2) 37 (8.8)
Type of AR, n (%)
PAR 120 (10.9) 61 (53.0) 1 (1.1) 11 (20.8) 30 (4.5) 30 (7.1)
SAR 435 (39.4) 51 (44.4) 17 (19.1) 23 (43.4) 274 (41.1) 137 (32.5)
PAR + SAR 444 (40.3) 0 71 (79.8) 17 (32.1) 359 (53.8) 237 (56.3)
Missing 104 (9.4) 3 (2.6) 0 2 (3.8) 4 (0.6) 17 (4.0)
Allergic comorbidities, n (%)
Asthma 267 (24.2) 19 (16.5) 43 (48.3) 17 (32.1) 179 (26.8) 267 (63.4)
Dermatitis/eczema 127 (11.5) 9 (7.8) 28 (31.5) 4 (7.6) 76 (11.4) 127 (30.2)
Food allergy/allergies 109 (9.9) 3 (2.6) 17 (19.1) 5 (9.4) 73 (10.9) 109 (25.9)
Severe allergic reactions 30 (2.7) 0 3 (3.4) 1 (1.9) 22 (3.3) 30 (7.1)
None 593 (53.8) 75 (65.2) 25 (28.1) 27 (50.1) 350 (52.5) 0
None 164 (14.9)
Baseline VAS score for overall AR symptoms (0–100 mm), mm
Mean 73.2 71.4 75.1 70.3 73.1 74.4
SD 13.4 13.4 13.7 13.1 13.5 13.4
AR, allergic rhinitis; ARP, allergic rhinitis subpopulation; IgE, immunoglobulin E; PAR, perennial allergic rhinitis; SAR, seasonal allergic rhinitis; 
SD, standard deviation; VAS, visual analog scale.
Table 3. Previous symptomatic AR treatments since last year
Full analysis set 
(N = 1,103), n (%)
Oral, nonsedating H1 antihistamine 506 (45.9)
INCS 471 (42.7)
Intranasal decongestant 191 (17.3)
INAH 177 (16.0)
Oral first-generation H1 antihistamine 162 (14.7)
Ocular H1 antihistamine 133 (12.1)
Oral or nebulized corticosteroid 99 (9.0)
Intranasal mast cell stabilizer 62 (5.6)
Oral leukotriene antagonist 50 (4.5)
Ocular mast cell stabilizer 42 (3.8)
Oral decongestant 26 (2.4)
Other 54 (4.9)
Unknown 24 (2.2)
AR, allergic rhinitis; INCS, intranasal corticosteroid; INAH, 
intranasal H1 antihistamine.
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Discussion
In this prospective, noninterventional, real-life 
study, MP-AzeFlu was associated with significantly re-
duced AR symptom severity according to AR-VAS 
scores. In past studies, VAS scores have shown concor-
dance with AR severity according to ARIA criteria [17, 
18]. In a study by Del Cuvillo and colleagues, VAS 
scores were used to classify AR symptom severity as 
mild (<40 mm), moderate (40–70 mm), or severe (>70 
mm) [19]. The baseline VAS scores in our study suggest 
that despite high baseline use of allergy medication in 
the past year, AR symptoms were severe, potentially re-
sulting in low quality of life.
In previous studies, VAS scores have also been used to 
evaluate the clinical relevance of changes in AR symp-
toms following treatment. Suggested cutoffs of clinical 
relevance for changes in VAS scores range from 10 to 23 
mm [17, 18, 20]. After 1 day of treatment with MP-Aze-
Flu, the mean VAS score improved by more than 10 mm 
in the full analysis set, suggesting rapid onset of action, 
with a clinically relevant improvement in scores. Further-
more, by day 3, a clinically important change of ≥23 mm 
was reported in nearly 50% of all patients (median change, 
22 mm); on the last day, >75% of patients had a clinically 
relevant improvement (upper quartile, 30 mm). The VAS 
scores for quality-of-life measures collected in this study 
provide additional support for the benefit of MP-AzeFlu 
treatment in the overall patient population, as well as in 
the subpopulations that were analyzed.
Use of MP-AzeFlu significantly reduced mean AR-
VAS scores from approximately 73–27 mm, reflecting a 
change from severe to mild AR symptom severity in the 
full analysis set and across all ARPs. Furthermore, these 
changes in scores reflect improvement in AR symptom 
control. All enrolled patients had uncontrolled AR at the 
time of enrollment (AR-VAS ≥50 mm) [16]. By the end 
of the study, the vast majority of patients (86.6%) fulfilled 
response criteria, and thus control criteria, for ≥1 time 
points.
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Study day
Last day
Full analyis set (VAS, mm)
ARP1 (IgE response to 1 environmental allergy without family history)
ARP2 (polyclonal IgE response to >5 allergens with family history)
ARP3 (nonallergic polyclonal IgE without family history)
ARP4 (intermediate phenotypes)
ARP5 (multimorbidity)
Fig. 1. Time course of mean VAS score (mm) for overall AR symptoms from day 0 to the last study day. AR, al-
lergic rhinitis; ARP, allergic rhinitis subpopulation; IgE, immunoglobulin E; SEM, standard error of the mean; 
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Fig. 2. Change in VAS score from day 0 to 
last day of the study (approximately day 14) 
in the general study population and ARPs 
for sleep quality (a), daily activities at work 
or school (b), daily social activities (c), and 
daily outdoor activities (d). ARP, allergic 
rhinitis subpopulation; IgE, immunoglob-
ulin E; SEM, standard error of the mean; 
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Assessment of daily activities: social (VAS, mm) – line plot of mean course
Subpopulations 5 and 6
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One of the goals of characterizing AR phenotypes was 
to provide a clinical framework for management deci-
sions [6]. Asthma is an example of a disease state with 
endotype- and phenotype-driven treatment paradigms 
[21]. Since the proposal of AR phenotypes based on IgE 
sensitization and comorbidities, no studies have evalu-
ated AR treatment safety and efficacy based on the disease 
phenotype classification system described by Bousquet 
and colleagues [6]. In the present study, we have charac-
terized treatment response to MP-AzeFlu based on AR 
phenotypes. Our results suggest that MP-AzeFlu is effec-
tive across the studied subpopulations, regardless of IgE 
sensitization, family history, or the presence of comor-
bidity, with no noted differences in effectiveness among 
subpopulations.
Study limitations include the observational nature of 
the study and the relatively small size of the different sub-
populations, particularly ARP3. However, participants 
were enrolled from several countries, providing evalu-
able datasets with no notable differences among coun-
tries.
Conclusion
MP-AzeFlu was associated with substantially re-
duced AR symptom severity and increased control from 
baseline to days 1, 3, and 7, as well as the last day, in the 
general study population and in all ARPs. Overall, more 
than three-quarters of patients achieved clinically sig-
nificant reductions in AR-VAS during the study. These 
results support MP-AzeFlu as an effective treatment for 
patients with moderate-to-severe AR, regardless of 
phenotype.
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